Unwarranted Fear About The Effects Of Radiation Leads To Bad Science Policy

Few issues have caused more fear and confusion than the question of the hazards of low-level radiation. There has been a remarkable failure to examine closely the evidence when discussing the issue and planning future studies. As a result, the public’s radiation phobia has been needlessly reinforced, and public money is being used on studies that are bound to be inconclusive. The problem arises, in part, because the general public—and even most scientists—are not aware that

Written byRosalyn Yalow
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The problem arises, in part, because the general public—and even most scientists—are not aware that exposure to ionizing radiation is only weakly carcinogenic. The evidence comes from a number of different studies. Among the 82,000 survivors of the Hiroshima-Nagasaki bombing, for example, an average exposure of 27 rem only raised the number of cancer deaths by 6% over the number expected in the absence of such exposure. Radiation-induced leukemia among the survivors began to appear two to three years after exposure, reached a peak at five to six years, and declined thereafter.

Studies in experimental animals have shown that the duration of the exposure, not just overall dose, is important. Acute exposure generally results in a much higher incidence of tumors than does the same dose delivered over a period of hours to days. It is possible that the Chernobyl accident may provide a direct answer about dose-rate effects in ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies